Scarica l'app Stockscreener
70.41
1.95%
-1.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$71.81
Aprire:
$71.88
Volume 24 ore:
984.37K
Relative Volume:
0.83
Capitalizzazione di mercato:
$7.19B
Reddito:
$1.64B
Utile/perdita netta:
$121.85M
Rapporto P/E:
45.72
EPS:
1.54
Flusso di cassa netto:
$-480.40M
1 W Prestazione:
-4.98%
1M Prestazione:
-31.68%
6M Prestazione:
-43.46%
1 anno Prestazione:
-45.61%
Intervallo 1D:
$69.81
$72.05
Intervallo di 1 settimana:
$69.81
$76.67
Portata 52W:
$69.81
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Nome
Sarepta Therapeutics Inc
Settore
Industria
Telefono
617-274-4000
Indirizzo
215 FIRST STREET, CAMBRIDGE, MA
Confronta SRPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
70.41 | 7.19B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-11-27 | Reiterato | Needham | Buy |
| 2024-11-25 | Iniziato | H.C. Wainwright | Sell |
| 2024-11-07 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Iniziato | Jefferies | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-07-29 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-05-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Outperform |
| 2023-12-13 | Ripresa | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-21 | Iniziato | Wedbush | Outperform |
| 2023-10-31 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-04 | Iniziato | Citigroup | Buy |
| 2023-03-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Reiterato | BTIG Research | Buy |
| 2022-12-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Reiterato | Needham | Buy |
| 2021-12-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-08-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-01-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-11 | Downgrade | UBS | Buy → Neutral |
| 2021-01-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Iniziato | Mizuho | Buy |
| 2019-11-01 | Iniziato | Guggenheim | Buy |
| 2019-08-21 | Reiterato | Needham | Buy |
| 2019-07-09 | Reiterato | Morgan Stanley | Overweight |
| 2019-07-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-11 | Reiterato | Credit Suisse | Outperform |
| 2018-10-12 | Iniziato | Bernstein | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Reiterato | RBC Capital Mkts | Outperform |
| 2018-09-14 | Ripresa | BofA/Merrill | Buy |
| 2018-09-06 | Iniziato | Credit Suisse | Outperform |
| 2018-08-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Reiterato | Robert W. Baird | Outperform |
| 2018-06-20 | Reiterato | Needham | Buy |
| 2018-06-19 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday? - MSN
Dravet Gene Therapy Tested in Mice, Sarepta’s Setback, and AstraZeneca Updates - Genetic Engineering & Biotechnology News
Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Safety Questions Loom in Duchenne as Dyne, Wave and Others Plan FDA Filings - BioSpace
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Wave strengthens case for accelerated approval, with more positive Duchenne data - Endpoints News
Sarepta stock plunges to 52-week low, touches $73 By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation - Markets Insider
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect - Markets Insider
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion - Yahoo Finance
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Is This Stock a Buy After a Massive 20% Drop in 1 Day? - Yahoo Finance
StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta - Genetic Engineering & Biotechnology News
PNC Financial Services Group Inc. Has $352,000 Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Scotiabank Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up - NewsBreak: Local News & Alerts
Nvidia, Nike, Sarepta Therapeutics, Protalix and more analyst calls of the week - Proactive Investors UK
This Is What Whales Are Betting On Sarepta Therapeutics - Benzinga
Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing - News & Insights
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Givi - Asianet Newsable
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 4% After Analyst Downgrade - Defense World
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
Deutsche Bank Aktiengesellschaft Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price - Defense World
Sarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT) - Defense World
Sarepta plunges after death linked to Elevidys (update) - MSN
Sarepta: Should Investors Run For The Exit? (NASDAQ:SRPT) - Seeking Alpha
Sarepta Therapeutics’ stock falls after patient dies of liver failure - MSN
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More - Zacks Investment Research
Regenxbio Rises After Duchenne Update And Sarepta Safety Scare - News & Insights
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation - Markets Insider
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades - PharmaVoice
In Wake of Elevidys Death, Duchenne Patient Community Vows to Push On - BioSpace
Sarepta Therapeutics (NASDAQ:SRPT) Given New $99.00 Price Target at Deutsche Bank Aktiengesellschaft - Armenian Reporter
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength? - Yahoo Finance
Pulse of the Market: Wednesday’s 10 Top Performers - Insider Monkey
Medical Stocks To Follow Today – March 18th - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Reach Out - ACCESS Newswire
Why Sarepta Therapeutics Inc. (SRPT) Went Up On Wednesday? - Yahoo Finance
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion - MSN
Sarepta’s gene therapy faced internal FDA doubts. Now, a teen has died - Healthcare Brew
Sarepta reports death of DMD patient given gene therapy, Elevidys - Muscular Dystrophy News
Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT) - Markets Insider
Sarepta Therapeutics’ SWOT analysis: strong Elevidys sales offset safety concerns - Investing.com
Sarepta Therapeutics Stock Sinks After Company Says Patient Taking Its Drug Dies - MSN
Sarepta's gene therapy under scrutiny after patient death - Medical Xpress
UBS maintains Sarepta stock Buy rating, $188 target despite concerns - Investing.com
UBS maintains Sarepta stock Buy rating, $188 target despite concerns By Investing.com - Investing.com UK
Sarepta’s Gene Therapy Under Scrutiny After Patient Death - ashepostandtimes.com
Sarepta Therapeutics Inc Azioni (SRPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):